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Endothelial Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4
Is Critical for Lymphatic Vascular Development and Function
Rachel J. Roth Flach,* Chang-An Guo,* Laura V. Danai,* Joseph C. Yawe, Sharvari Gujja, Yvonne J. K. Edwards, Michael P. Czech
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
Themolecular mechanisms underlying lymphatic vascular development and function are not well understood. Recent studies
have suggested a role for endothelial cell (EC) mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) in developmen-
tal angiogenesis and atherosclerosis. Here, we show that constitutive loss of ECMap4k4 in mice causes postnatal lethality due to
chylothorax, suggesting that Map4k4 is required for normal lymphatic vascular function. Mice constitutively lacking ECMap4k4
displayed dilated lymphatic capillaries, insufficient lymphatic valves, and impaired lymphatic flow; furthermore, primary ECs
derived from these animals displayed enhanced proliferation compared with controls. Yeast 2-hybrid analyses identified the Ras
GTPase-activating protein Rasa1, a known regulator of lymphatic development and lymphatic endothelial cell fate, as a direct
interacting partner for Map4k4. Map4k4 silencing in ECs enhanced basal Ras and extracellular signal-regulated kinase (Erk) ac-
tivities, and primary ECs lackingMap4k4 displayed enhanced lymphatic ECmarker expression. Taken together, these results
reveal that ECMap4k4 is critical for lymphatic vascular development by regulating EC quiescence and lymphatic EC fate.
The vascular system is comprised of arteries and veins, whichdeliver nutrients to organs via capillaries and lymphatic ves-
sels, which in turn reabsorb fluid from tissues for delivery back
into the circulation. Both blood and lymphatic vessels are lined
with endothelial cells (ECs), which are critical for the function and
maintenance of both vascular networks (1). Normal lymphatic
vascular function is required for maintaining fluid balance, im-
mune surveillance, and lipid homeostasis (2, 3). In contrast, lym-
phatic vascular dysfunction is associated with numerous diseases,
including developmental abnormalities, cancer metastasis, and
lymphedema (4, 5). Though common pathways are involved in
early vascular development, specialized molecules are required to
drive and maintain lymphatic endothelial cell fate specification
both during and after development (6, 7), and the signaling path-
ways that specifically promote lymphatic vascular development
are still not well understood.
Our laboratory recently demonstrated that mitogen-activated
protein kinase kinase kinase kinase 4 (Map4k4) has a profound
role within the endothelium to promote atherosclerosis develop-
ment and lymphocyte recruitment in inducible, endothelium-
specific Map4k4 knockout animals on an Apoe/ background
(8). The present studies were designed to investigate the role of
Map4k4 in endothelial cell function in more detail. We observed
that mouse pups lacking endothelial Map4k4 displayed postnatal
lethality due to chyle leakage into the thoracic cavity after birth
(chylothorax) when constitutively expressed Cdh5 Cre (Ve-cad-
herin Cre) (9) was used to delete Map4k4 in the endothelium.
Furthermore, animals constitutively lacking EC Map4k4 dis-
played dilated lymphatic capillaries, abnormal valves, and im-
paired lymphatic flow. Yeast 2-hybrid analysis of Map4k4 identi-
fied the protein RAS p21 protein activator 1 (Rasa1), which is
critical for lymphatic development and is a negative regulator of
Ras–mitogen-activated protein kinase (Ras-MAPK) signaling
(10), as a direct binding partner for Map4k4. Loss of Map4k4 in
ECs enhanced Ras and extracellular signal-regulated kinase (Erk)
activities and ameliorated EC quiescence in culture. Taken to-
gether, these results demonstrate a complex and critical role for
lymphatic endothelial Map4k4 in development.
MATERIALS AND METHODS
Mouse models. The University of Massachusetts Medical School Institu-
tional Animal Care and Use Committee approved all of the animal pro-
cedures.Map4k4 Flox/Flox animals, Cdh5 Cre animals [B6.Cg-Tg(Cdh5-
cre)7Mlia/J; Jackson Laboratories], and Map4k4 inducible endothelial
cell-specific knockout (iECKO) mice [Cdh5(PAC)-CreERT2] have been
previously described (8). At 6 to 8 weeks of age, male Flox/Flox and Flox/
Flox/Cre littermates were injected with 1 mg tamoxifen/day in corn oil
(Sigma) for 5 days and maintained on a chow diet. The mice were eutha-
nized by CO2 inhalation, followed by bilateral pneumothorax or by de-
capitation if younger than postnatal day 12 (p12). Footpads were injected
with 25 l of 2% Evans blue dye (Sigma) in phosphate-buffered saline
(PBS), and lymph nodes were visualized 1 h later. No statistical methods
were used to predict sample size, no randomization was performed, and
the investigations were not blinded.
Cell culture and transfection.Humanumbilical vein endothelial cells
(HUVECs) and human dermal lymphatic endothelial cells (HDLECs)
were purchased fromClonetics and grown in endothelial growthmedium
2 (EGM-2) or EGM-2microvascular (EGM-2MV)medium, respectively.
The cells were transfected and maintained as previously described (8).
Primary mouse lung endothelial cells (MLECs) were prepared by diges-
tion and immune isolation, as previously described (8). The adenoviruses
used for overexpression were a generous gift from Diane Barber (11).
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HUVECs were infected with 0.25l virus/mlmedium for 4 h and lysed 48
h after infection.
RNA isolation and quantitative RT-PCR. Total RNA was isolated,
cDNA was prepared, and quantitative reverse transcription (qRT)-PCR
was performed as previously described (8). The primer sequences were as
follows:Map4k4 F, CATCTCCAGGGAAATCCTCAGG, andR, TTCTGTA
GTCGTAAGTGGCGTCTG;Cd31 F, ACGCTGGTGCTCTATGCAAG, and
R, TCAGTTGCTGCCCATTCATCA; Cdh5 F, CACTGCTTTGGGAGCC
TTC, and R, GGGGCAGCGATTCATTTTTCT; Kdr F, TTTGGCAAATA
CAACCCTTCAGA, and R, GCAGAAGATACTGTCACCACC; Lyve1 F,
CAGCACACTAGCCTGGTGTTA, and R, CGCCCATGATTCTGCATG
TAGA; Prox1 F, AGAAGGGTTGACATTGGAGTGA, and R, TGCGTGT
TGCACCACAGAATA; Flt4 F, CTGGCAAATGGTTACTCCATGA, and
R, ACAACCCGTGTGTCTTCACTG; Sox18 F, CCTGTCACCAACGTCT
CGC, and R, GCAACTCGTCGGCAGTTTG; Pdpn F, ACCGTGCCAGT
GTTGTTCTG, and R, AGCACCTGTGGTTGTTATTTTGT; Vegfc F, GA
GGTCAAGGCTTTTGAAGGC, and R, CTGTCCTGGTATTGAGGG
TGG; and Ccnd2 F, GAGTGGGAACTGGTAGTGTTG, and R, CGCACA
GAGCGATGAAGGT.
Western blotting. Cells were lysed in lysis buffer (150 mMNaCl, 100
mM Tris, 5 mM EDTA, 1% Triton X-100 for cell lysates; 100 mM NaCl,
100 mMTris, 5 mM EDTA, 1% Triton X-100 for immunoprecipitations)
with 1HALT protease and phosphatase inhibitors (Thermo Scientific).
The lysates were run on SDS-PAGE gels and transferred to nitrocellulose
membranes. The lysates were immunoprecipitatedwith anti-RasGTPase-
activating protein (GAP) antibodies (SantaCruz; 2g) or anti-mouse IgG
(2 g). The membranes were immunoblotted with anti-MAP4K4
A301-503A (Bethyl; 1:2,000), phosphorylated-Erk (P-Erk) 4370 (Cell
Signaling Technology; 1:1,000), total Erk1 sc-93 (Santa Cruz; 1:1,000),
Rasa1/Ras GAP (Santa Cruz B4-F8; 1:250), or Ras (Thermo-Pierce;
1:200) antibodies.
Immunostaining.Whole-mount immunostaining was performed on
tissues that had been fixed in 10% formalin for 2 to 6 h. Retinas were
blocked overnight in 10% bovine serum albumin (BSA) and 0.3% Triton
X-100 in PBS at 4°C; stained overnight with Isolectin B4 (Life Technolo-
gies; I21411; 1:40) in 100mMMgCl2, 100mMCaCl2, 10mMMnCl2, and
1% Triton X-100 in PBS at 4°C; and washed 3 times for 20 min each time
in 5% BSA, 0.15% Triton X-100 in PBS at room temperature. von Wille-
brand factor (vWf) (Abcamab9378; 1:200), Lyve-1 (Abcam14917; 1:500),
and Prox-1 (Abcam 37128; 1:200) immunostaining was performed in 3%
goat serumand 2%BSA in 0.3%Triton overnight, followed by fluorescent
secondary antibodies (Life Technologies). Tissues were mounted in Pro-
Long Gold (Life Technologies). Whole-mount images were visualized
in flattened 25-m z-stacks with a Solamere Technology Group mod-
ified Yokogawa CSU10 spinning-disk confocal system with a Nikon
TE-2000E2 inverted microscope at 10 or 20 magnification. Images
were acquired withMetaMorph software, version 6.1 (Universal Imaging,
Downingtown, PA). A Zeiss Axiovert 100 inverted microscope with a 5
or 10 objective and an AxioCam HRm camera was used for retina and
intestine images. The images were quantified using ImageJ analysis soft-
ware.
Proliferation assays. Primary MLECs were used at passage 3 for all
experiments. For cell-counting assays, 25,000 cells were plated in 24-well
plates on day 0. On day 1, the cells were trypsinized and counted. On days
2 to 4, the cells were trypsinized and counted, and this value was normal-
ized to the count from day 1. Cell numbers were expressed as fold change
from day 1. In parallel, equal numbers of MLECs were plated on 6-well
plates. To assess proliferation, the cells were stained for Ki67 (phycoeryth-
rin [PE]; BD) after a rest period. Apoptosis was induced by starving con-
fluent MLECs for 72 h as described previously (10), and serum-fed or
starved cells were stained with an annexin V apoptosis assay kit (BD)
according to the manufacturer’s instructions. Cell cycle analysis was per-
formed using a fluorescein isothiocyanate (FITC) bromodeoxyuridine
(BrdU) flow kit (BD) according to the manufacturer’s instructions. The
data were collected on an LSRII flow cytometer (BD) and were analyzed
with FlowJo software. Samples were gated for scatter and single cells.
Gates were drawn based on fluorescence minus one (FMO) controls. A
total of at least 100,000 events were recorded.
Ras-GTP levels. HUVECs were transfected with scrambled or
MAP4K4 small interfering RNA (siRNA), as previously reported (8). The
cells were serum starved overnight prior to the assay. The active Ras pull-
down and detection kit (Thermo-Pierce) was used according to the assay
instructions. Briefly, glutathione S-transferase (GST)–Raf1 was used to
pull down active Ras from cell lysates with glutathione beads, and the
amount of active Ras in the pulldowns was normalized to that in cell
lysates.
Yeast 2-hybrid assay. The Clontech Matchmaker gold yeast 2-hybrid
system was used to screen a whole mouse genome library. A 31.5-kDa
fragment ofmurineMap4k4 encoding the N-terminal kinase domain or a
39.5-kDa fragment of murine Map4k4 encoding the C-terminal citron
homology domain (CNH)was cloned into the pGBKT7 plasmid using the
In-Fusion advantage kit (Clontech) and used as bait. Screening and bind-
ing partner identification was performed according to the assay instruc-
tions.
Fluid biochemical analysis. Fluidwas collected from the thoracic cav-
ity, and blood was collected via cardiac puncture from the same Map4k4
Cdh5 Cre animals prior to death. Triglyceride (Sigma) and cholesterol
(Pointe Scientific) contents were assessed by colorimetric methods, and
albumin (Abcam) and fibrinogen (Abcam) contents were assessed by en-
zyme-linked immunosorbent assay (ELISA). Values were obtained for
both fluids, and a ratio (thoracic fluid/blood) was calculated from the
values obtained. Colorimetric assays and ELISAs were performed accord-
ing to the manufacturers’ instructions.
Microarray analysis. RNA was isolated, using TriPure (Roche), from
three independent experiments, and cDNA synthesis and in vitro tran-
scription were performed using the AmbionWT expression kit (Ambion,
Carlsbad, CA). Second-strand cDNAwas labeled with the AffymetrixWT
terminal-labeling kit, and samples were hybridized to three different Af-
fymetrix Genechip Human Gene 1.0 ST arrays. The Microarray Compu-
tational Environment (MACE) was used to process raw oligonucleotide
microarray data as previously described (12), and KEGG analysis was
performed in MACE internally using the R package KEGG.db.
Statistical analysis. For the microarray, the differential expression
analysis of genes in two groups was performed using Student’s t test in-
ternally within MACE (12). A two-tailed Student t test was used to com-
pare two groups in Microsoft Excel. Two-way analysis of variance
(ANOVA)with the Sidak posttest was used to comparemultiple groups in
GraphPad Prism 6.0. A P value of0.05 was considered to be statistically
significant. Variance was estimated using the standard error of the mean.
Microarray data accession number. The data described in this article
are accessible via GEO series accession no. GSE78107 (http://www.ncbi
.nlm.nih.gov/geo/query/acc.cgi?accGSE78107).
RESULTS
Mice lacking endothelial Map4k4 display lymphatic defects.
Previous studies conducted in our laboratory to assess the role of
Map4k4 in the endothelium utilized mice with endothelium-spe-
cific short hairpin RNA (shRNA)-mediated constitutive Map4k4
knockdown or inducible endothelial cell-specific Map4k4 Flox/
Flox animals (8). We observed during the course of these studies
that mice constitutively lacking endothelial Map4k4, which were
developed by crossing Map4k4 Flox/Flox animals to Ve-cadherin
Cre animals (Map4k4 Cdh5 Cre), did not survive past weaning
age. Though thesemice were born at nearlyMendelian ratios (Ta-
ble 1), less than 5%ofMap4k4Cdh5Cremice survived toweaning
age, and the median time of death was p9 (Fig. 1A).
Map4k4 Cdh5 Cre animals displayed rapid, shallow breathing
prior to death, and upon dissection, a milky white fluid was ob-
served in the thoracic cavities of these animals (Fig. 1B). Though
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this fluid was often acellular (Fig. 1C), we performed biochemical
analyses to compare the properties of the thoracic fluid to those of
the blood. We observed that the triglyceride content in the tho-
racic fluid was much higher, concomitant with lower levels of
cholesterol and fibrinogen than in blood from the same animals
(Table 2). The properties of the thoracic fluidwere consistent with
that of chylous leakage, which led us to conclude that the animals
succumbed to chylothorax.
The chyle leakage observed in Map4k4 Cdh5 Cre animals sug-
gested that the lymphatic vascular system might be affected in
these animals. The lymphatic vascular system is comprised of a
network of lymphatic capillaries, which drain fluid containing
plasma proteins and immune cells in response to changes in in-
terstitial pressure, and lacteals in the small intestine that absorb
dietary lipids as chylomicrons (2, 4, 5). Thus, to assess the lym-
phatic vascular morphology, immunostaining for Lyve-1, a lym-
phatic capillary marker, was performed in the ear skin and mes-
enteries of Flox/Flox and Map4k4 Cdh5 Cre animals. While a
typical network of lymphatic capillaries was observed in Flox/Flox
mice,Map4k4 Cdh5Cre animals displayed a 57% increase in lym-
phatic vascular density, which was attributed in part to a 58%
increase in the lymphatic vascular diameter (Fig. 2A to C). Simi-
larly, a 60% increase in the Lyve-1-positive area and a 51% in-
crease in the Lyve-1-positive-vessel diameter was observed in
Map4k4 Cdh5 Cre intestinal cross sections compared with con-
trols (Fig. 3D to F).
Lymphatic capillaries drain into larger collecting vessels, which
pump chyle against gravity into the thoracic duct and eventually
into the venous circulation (4, 13). Chyle backflow from these
collecting vessels is prevented by a series of valves (14). To assess
the valve morphology, immunostaining with Prox-1, a lymphatic
marker that concentrates at lymphatic valves (15), was performed
in themesenteries of p2 Flox/Flox andMap4k4Cdh5Cre animals.
Prox-1 staining in Flox/Flox animals revealed a typical V-like
shape, indicating lymphatic valves. However, in Map4k4 Cdh5
Cre mice, Prox-1 immunostaining revealed abnormal Prox-1 lo-
calization, and the majority of lymphatic valves displayed an al-
tered, open morphology (Fig. 2D). Furthermore, there was a 61%
reduction in the number of valves per millimeter mesentery in
Map4k4 Cdh5 Cre animals (Fig. 2E). These results indicate that
endothelial Map4k4 is critical for lymphatic-valve development,
and thus, Map4k4 depletion manifests in dilated lymphatic capil-
laries and lymphatic leakage.
To assess lymphatic function, Evans blue dye was injected into
one rear footpad of live p16 Flox/Flox and Map4k4 Cdh5 Cre
mice. In Flox/Flox animals, the dye migrated to the inguinal and
iliac lymph nodes in a typical pattern within 60min postinjection.
However, in Map4k4 Cdh5 Cre mice, the dye did not migrate to
the iliac lymph node, and while dye was observed in the inguinal
lymph node, an excess of dye was observed throughout the skin
capillaries (Fig. 2F to G). These data demonstrate that Map4k4
Cdh5 Cre lymphatic vessels do not pump fluid sufficiently, thus
promoting fluid stasis and accumulation within superficial lym-
phatic capillaries.
Previous reports suggested a role for endothelial Map4k4 in
developmental angiogenesis using endothelium-specific Tie2 Cre,
Rosa26-inducible whole-body deletion, and pharmacological in-
hibitors (16). To assess developmental vascularization inMap4k4
Cdh5 Cre mice, isolectin B4 (iB4) staining of p6 Flox/Flox and
Map4k4 Cdh5 Cre retinas was performed. Similar to the previous
study, we also observed reduced retinal outgrowth (enhanced
avascular area), as well as increased vascular density in Map4k4
Cdh5 Cre mice compared with controls (Fig. 3A to C). However,
no alterations in intestinal blood vessel area or diameter were ob-
served, as assessed by vWf immunostaining (Fig. 3G to I). These
data suggest that loss of Map4k4 using Cdh5 Cre results in only
mild blood vascular phenotypes.
Enhanced EC proliferation in Map4k4 iECKOmice. The en-
hanced lymphatic and blood vascular density phenotypes observed
in development (Fig. 2 and 3) suggested that Map4k4 may affect EC
growth. Thus, primary MLECs were isolated from adult C57BL/6J
Map4k4 Flox/Flox or Map4k4 inducible EC-specific knockout
iECKO) mice, which have been previously described (8). To func-
tionally assess whether ECs lacking Map4k4 displayed an enhanced
capacity to proliferate, subconfluent Flox/Flox and Map4k4 iECKO
primaryMLECs were plated and counted daily for 4 days in parallel.
Whereas the doubling time of Flox/FloxMLECswas 60.1 h,Map4k4
iECKOMLECs doubled 33% faster (45.0 h), which was significantly
increased fromcontrols (Fig. 4A). Furthermore, this enhancement in
proliferation was accompanied by nearly a 2-fold increase in expres-
sion of the proliferation marker Ki67 in Map4k4 iECKO MLECs
comparedwith Flox/FloxMLECs (Fig. 4B). The changes observed in
FIG 1 Mice constitutively lacking EC Map4k4 develop chylothorax. (A)
Map4k4 (M4K4) Cdh5 Cre animals die at a median of p8.5 (n  26; P 
0.0001). (B)Map4k4 Cdh5 Cre animal at p7 displaying chylothorax. (C) Fluid
from the thoracic cavity of a representative Map4k4 Cdh5 Cre animal.
TABLE 1 Predicted genotypes of pupsa
Genotype
Predicted Actual
No. % No. %
flox/ 37.5 25 54 36
flox/flox 37.5 25 34 22.7
flox/ cdh5 cre 37.5 25 33 22
flox/flox cdh5 cre 37.5 25 23 15.3
a Map4k4 flox/flox cdh5 cre pups born compared with the predicted Mendelian ratio
(n 150).
Roth Flach et al.
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cell numberswerenotdue toapoptosis, as annexinVstainingwasnot
altered between genotypes (Fig. 4C). These results suggest that
Map4k4 depletion in ECs results in increased hyperplasia due to en-
hanced proliferation.
To elucidate howMap4k4 altered proliferation, the cell cycle of
primaryMLECs derived fromFlox/Flox andMap4k4 iECKOmice
was assessed using BrdU and 7-aminoactinomycin D (7-AAD)
incorporation. After an overnight pulse of BrdU, similar percent-
TABLE 2 Biochemistry of thoracic fluida
Mouse
Triglycerides Cholesterol Albumin Fibrinogen
Amt (mg/dl)
Ratio
Amt (mmol/liter)
Ratio
Amt (g/liter)
Ratio
Amt (mg/liter)
RatioThoracic fluid Blood Thoracic fluid Blood Thoracic fluid Blood Thoracic fluid Blood
1 149.2 66.6 2.2 64.0 100.8 0.6 26.3 33.6 0.8 867.4 1,115.1 0.8
2 230.6 162.7 1.4 54.5 103.2 0.5 26.4 34.8 0.8 858.4 939.6 0.9
3 276.8 98.0 2.8 56.2 101.1 0.6 25.5 35.6 0.7 875.7 1,096.4 0.8
4 566.6 133.3 4.3 124.5 203.1 0.6 25.1 24.0 1.0 816.7 949.6 0.9
5 1,354.5 100.7 13.4 95.6 105.8 0.9 26.7 23.4 1.1 884.6 1,036.9 0.9
6 537.6 239.7 2.2 122.8 219.6 0.6 25.9 25.2 1.0 862.4 1,199.1 0.7
a Peripheral blood and fluid from the thoracic cavity were collected from Map4k4 Cdh5 Cre pups prior to death. The ratios of the amounts of analytes in the thoracic fluid to those
in the blood are shown.
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FIG 2 Lymphatic abnormalities in Map4k4 Cdh5 Cre mice. (A to C) Ear skin from p6 Flox/Flox or Map4k4 Cdh5 Cre animals was stained with Lyve-1 as a
marker of lymphatic capillaries. (A)Representative images. Scale bars, 100m. (B)Vessel density as ameasure of percent stained area normalized to the Flox/Flox
area. (C) Average vessel diameter as normalized to the Flox/Flox diameter. (D and E)Mesenteries from p2 Flox/Flox or Map4k4 Cdh5 Cre animals were stained
with Prox-1 as amarker of lymphatic valves. (D)Representative images. The arrowheads indicate valves. Scale bars, 100m. (E)Numbers of valves permillimeter
mesentery as normalized to Flox/Flox animals. (F and G) p16 pups were injected with Evans blue dye in the footpad, and themice were sacrificed to visualize dye
in lymph nodes 1 h later. The images are representative of at least 4 animals per genotype. (F) Inguinal lymph nodes; the arrowhead indicates enhanced capillary
visualization in the skin ofMap4k4 Cdh5 Cremice. (G) Iliac lymph nodes; the arrowheads indicate a lack of dye in iliac lymph nodes ofMap4k4 Cdh5 Cremice.
The error bars represent standard errors of the mean. **, P 0.005; n 4 to 6.
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ages of MLECs were identified in G0/G1 and S phases of the cell
cycle; however, therewas a significant (30%) reduction ofMap4k4
iECKO MLECs in the G2/M transition (BrdU
 7-AAD; 28%
Flox/Flox versus 16%Map4k4 iECKO) (Fig. 4D). These data sug-
gest that loss of Map4k4 in ECs alters cell cycle progression.
To identify whether loss of Map4k4 in ECs altered cell cycle
gene expression, amicroarray analysis was performed inHUVECs
after treatment with scrambled or MAP4K4 siRNA. Of the genes
regulated byMAP4K4 loss, several were involved in cell cycle reg-
ulation, G2/M transition, and mitosis (Fig. 4E). KEGG analysis of
the most highly up- or downregulated (|1.5|-fold) genes re-
vealed that loss of MAP4K4 affected the following pathways: cell
cycle (P  2  106), p53 signaling (P  5  104), oocyte
meiosis (P  0.001), progesterone-mediated oocyte maturation
(P 0.001), hematopoietic cell lineage (P 0.002), and cytokine-
cytokine receptor interaction (P 0.05).
Cell cycle gene expression was also affected by Map4k4 loss in
MLECs, as Map4k4 iECKO MLECs demonstrated a significant
2-fold increase in Ccnd2 mRNA expression compared with Flox/
Flox controls (Fig. 4F). These data demonstrate that loss of
Map4k4 in HUVECs and MLECs alters the expression of genes
involved in cell cycle progression.
MAP4K4directly bindsRASA1andnegatively regulates ERK
activity and lymphatic cell fate.Toelucidate themolecularmech-
anisms by whichMap4k4 operates in ECs, a yeast 2-hybrid screen
was performed in which the NH2-terminal kinase domain or the
FIG 3 Vascular abnormalities inMap4k4 Cdh5 Cremice. (A to C) Retinas were isolated from p6 Flox/Flox orMap4k4 Cdh5 Cre pups and stained with isolectin
B4. (A) Representative images (5 magnification, scale bars  250 m [top]; 20 magnification, scale bars  50 m [bottom]). (B) Quantitation of retinal
outgrowth as the diameter from the optic nerve to the perimeter as normalized to Flox/Flox (*, P 0.05; n 5 or 6). (C) Vessel density quantified as percent
stained area and normalized to Flox/Flox (*, P  0.05; n  6 or 7). (D to I) Intestines were isolated from p18 Flox/Flox or Map4k4 Cdh5 Cre pups. (D to F)
Intestinal cross sections were stained with Lyve-1 as a lymphatic capillary marker and with 4=,6-diamidino-2-phenylindole (DAPI) to visualize villi. (D)
Representative images; scale bars, 50m. (E) Quantitation of Lyve-1-stained area as normalized to Flox/Flox animals. (F) Quantitation of Lyve-1-stained-vessel
diameter as normalized to Flox/Flox animals (n 4 to 6). (G to I) Intestinal cross sections were stained with vWF as a blood endothelial marker and with DAPI
to visualize villi; scale bars, 50 m. (G) Representative images. (H) Quantitation of vWF-stained area as normalized to Flox/Flox animals. (I) Quantitation of
vWF-stained-vessel diameter as normalized to Flox/Flox animals (n 4 to 6). The error bars represent standard errors of the mean.
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C-terminal CNH domain of Map4k4 was used as bait to screen a
whole-genome library. Though several unique hits were obtained
using the kinase or the CNH domain (Table 3), we focused on
Rasa1, a GAP for Ras (also known as p120 RasGAP), as an inter-
acting partner of the CNH domain of Map4k4. We focused on
Rasa1 for several reasons. First, previous studies have demon-
strated direct and indirect interactions ofMap4k4 and the adapter
protein Nck (17), which directly binds Rasa1 (18). Second, an
additional study demonstrated that Map4k4 is in a complex with
Rasa1, although it was hypothesized in that study that the binding
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as assessed by flow cytometry (n 6 or 7). (D) The cell cycle was assessed by BrdU and 7-AAD staining using flow cytometry (G0/G1, BrdU
 7-AAD; S, BrdU;
G2/M, 7- AAD
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of the two proteins was indirect (19). Third, RASA1mutations are
associated with lymphatic dysfunction in humans (20). Finally,
inducible loss of Rasa1 in mice causes lymphatic vascular prolif-
eration phenotypes, as well as chyle leakage and death, which is a
phenotype similar to the one we observed in Map4k4 Cdh5 Cre
mice (10, 20). Interestingly, mapping of the Y2H clone that inter-
actedwithMap4k4determinedthatMap4k4boundtheGAPdomain
ofRasa1 (Fig. 5A), suggesting thatMap4k4may affectRasa1 function
to dampenRas activity.We confirmed the association of RASA1 and
MAP4K4 in HUVECs by immunoprecipitating endogenous RASA1
and immunoblotting overexpressed wild-type (WT) MAP4K4 or a
MAP4K4 mutant that renders it kinase inactive (DN), which we ex-
pressed in an effort to form amore stable complex with RASA1 (Fig.
5B). Endogenous complex formation of RASA1 andMAP4K4was
also detected in HDLECs by coimmunoprecipitation (Fig. 5C).
Rasa1 promotes the hydrolysis of Ras-GTP to Ras-GDP and
thus inactivates the Ras-Erk cascade (21). To determine whether
MAP4K4 affected Ras-MAPK pathway levels or activity, HUVECs
were transfected with scrambled orMAP4K4 siRNA for 48 h. No-
tably, there were no alterations in total levels of RASA1 after
MAP4K4 depletion (Fig. 5D). The cells were serum starved, and
RAS-GTP loading was assessed using GST-Raf1 to pull down ac-
tive RAS. A 2-fold increase was observed in the amount of RAS
bound to GST-Raf1 when normalized to total RAS levels after
MAP4K4 silencing, suggesting that loss of MAP4K4 in ECs pro-
motes basal RAS activation (Fig. 5E).
MAP4K4 silencing also led to increased p-ERK levels as nor-
malized to total ERK in HUVECs (Fig. 5F), HDLECs (Fig. 5G),
and MLECs (Fig. 5H) after serum starvation. However, acute
VEGF-C stimulation induced transient ERK activation with sim-
ilar temporal regulation in scrambled andMAP4K4 siRNA-trans-
fected HUVECs and HDLECs, as well as primary MLECs lacking
Map4k4 (Fig. 5F to H). These results suggest that MAP4K4 is
critical to maintain EC quiescence at the level of ERK activation
but is dispensable for growth factor-induced ERK activation.
The Ras-Erk axis controls lymphangiogenesis and cell fate by
activating a series of genes that are necessary and sufficient to
maintain a lymphatic EC signature, including the transcription
factors Sox18 and Prox1 (22). Thus, we assessed whether loss of
Map4k4 promoted a lymphatic endothelial cell fate, which may
contribute to the chyle leakage phenotype that was observed (Fig.
1). Primary MLECs were isolated from Flox/Flox and Map4k4
iECKO mice, and qRT-PCR was performed for a number of en-
dothelial marker genes. While expression of the pan-endothelial
marker genesCd31,Cdh5, andKdr (Vegfr2) did not differ between
genotypes, the lymphatic endothelial marker genes Lyve1, Prox-1,
Flt4 (Vegfr3), and Sox18 were all upregulated in Map4k4 iECKO
MLECs compared with Flox/Flox ECs, whereas no difference was
observed in the collecting vessel marker gene Pdpn (Fig. 5I). In-
terestingly, reduced mRNA levels of Vegf-c, encoding a Vegfr3
ligand that promotes lymphatic endothelial fate and function,
were observed in Map4k4 iECKOMLECs, suggesting that the cell
TABLE 3 Yeast 2-hybrid screen results
Domaina Occurrenceb Protein Confirmed in yeastc
Kinase 44 von Hippel-Lindau binding protein (Vbp1) Yes
Kinase 3 Filamin, alpha Yes
Kinase 2 Fatty acid binding protein 4, adipocyte (Fabp4) Yes
Kinase 1 Proliferation-associated 2G4 (Pa2g4)/Erb binding protein 1 (EBP1) Yes
Kinase 3 CD48 antigen No
Kinase 1 Ubiquitin-conjugating enzyme E2N No
Kinase 1 HFM1; ATP-dependent DNA helicase homolog ND
Kinase 1 Dynactin 4 No
Kinase 1 Glycine amidinotransferase (L-arginine::glycine amidinotransferase) (Gatm) ND
Kinase 1 Complement component 4 binding protein (C4bp) No
Kinase 2 Inter-alpha (globulin) inhibitor H5 (Itih5) No
Kinase 2 Centrosome- and spindle pole-associated protein 1 (Cspp1) ND
Kinase 1 Leukotriene A4 hydrolase (Lta4h) No
Kinase 1 Nedd8 (neural precursor cell overexpressed developmentally downregulated gene 8) ND
Kinase 1 Ribosomal protein S20 (Rps20) ND
Kinase 2 Ras p21 protein activator 2 (Rasa2) ND
Kinase 1 Riken cDNA 4932415G16 gene ND
Kinase 1 Mus musculus titin (Ttn), transcript variant N2-A, transcript variant N2-B, mRNA No
CNH 15 Proteasome (prosome and macropain) 26S subunit, ATPase, 6 (Psmc6) Yes
CNH 10 Kruppel-like factor 4 (gut) (Klf4) Yes
CNH 2 RAS p21 protein activator 1 (Rasa1) ND
CNH 2 Cell division cycle 123 homolog (Saccharomyces cerevisiae) (Cdc123) ND
CNH 2 Bromodomain PHD finger transcription factor (Bptf)/FALZ ND
CNH 1 Bobby sox homolog (Drosophila) (Bbx)/HBP2 ND
CNH 1 Transcription factor 4 (Tcf4) Yes
CNH 1 SUB1 homolog (S. cervesiae) Yes
CNH 1 Annexin A8 (Anxa8) Yes
CNH 1 Cspp1 ND
a The Clontech matchmaker gold yeast 2-hybrid system was used to screen a whole human genome library with the MAP4K4 N-terminal kinase domain (Kinase) or C-terminal
CNH as bait.
b Occurrence, number of times a protein was identified in the screen.
c Confirmed in yeast indicates whether isolated clones were retransfected into yeast to verify the interaction. ND, not done.
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fate effect may be unrelated to enhanced ligand production (Fig.
5I). Thus, Map4k4 is important for maintenance of EC fate and
quiescence by modulation of the Ras-Erk signaling pathway.
These results collectively are consistent with the observations that
loss of endothelial Map4k4 in vivo causes lymphatic vascular hy-
perproliferation and leakage, resulting in developmental and
functional abnormalities (Fig. 5G).
DISCUSSION
The major findings of the present study demonstrate that the en-
dothelial protein kinase Map4k4 is required for lymphatic vascu-
lar development. Constitutive endothelial Map4k4 deletion using
Cdh5/Ve-cadherin Cre revealed that Map4k4 has a fundamental
role in lymphatic vascular development, as Map4k4 Cdh5 Cre
mice displayed postnatal lethality (Fig. 1) due to chylothorax (Ta-
ble 2), which was accompanied by lymphatic capillary dilation,
reduced lymphatic collecting valve numbers, and impaired lym-
phatic flow (Fig. 2).
Recent studies by Vitorino et al. (16) used Tie2 Cre and Rosa26
deletion models to demonstrate that Map4k4 is important for
developmental angiogenesis and retinopathy in mice. Though we
observed delayed retinal outgrowth and enhanced vascular den-
sity in Map4k4 Cdh5 Cre retinas at p6, which was similar to the
findings of Vitorino et al., no alteration in blood endothelial mor-
phology or area was observed in the intestines of Map4k4 Cdh5
Cre mice (Fig. 3). Furthermore, these authors demonstrated le-
thality at embryonic day 16.5 (e16.5) in this model (16). Because
the Tie2 Cre model deletes genes in endothelial cells earlier than
Cdh5 (Ve-cadherin) (23), it is not surprising that Map4k4 Cdh5
Cre animals displayed delayed lethality (Fig. 1). Notably, although
Vitorino et al. did not report any lymphatic phenotypes, edema
was observed in Map4k4 Tie2 Cre knockout mice (16), which is
indicative of lymphatic dysfunction (24).
Our previous studies using Apoe/mice determined that en-
dothelialMap4k4was critical for atherosclerosis development (8).
Recent studies have demonstrated that the high plasma choles-
terol content in Apoe/mice contributes to impaired lymphatic
drainage, which is accompanied by lymphatic dysfunction and
regression (25). However, follow-up studies reported an active
role for the lymphatic vascular system in reverse cholesterol trans-
port of lipid-laden macrophages in atherosclerosis; thus, the dys-
functional lymphatic network in hypercholesterolemic mice con-
tributes to disease (26, 27). Though we did not observe chyle
leakage phenotypes in mice lacking endothelial Map4k4 on an
Apoe/ background, we cannot rule out, based on the studies
presented here, the possibility that the lymphatic endothelium is
partially responsible for ameliorating atherosclerosis in Apoe/
mice lacking endothelial Map4k4. Thus, future studies will inves-
tigate the role of reverse cholesterol transport in the improved
atherosclerosis phenotypes observed in these animals, as well as a
lymphatic-specific role for Map4k4 in atherosclerosis.
Among many proteins identified as Map4k4 binding partners
in a yeast 2-hybrid screen (Table 3), Rasa1 was chosen for further
assessment. Few mouse models display lymphatic dysfunction
and chyle leakage, and these mice genetically map out a signaling
pathway that is critical for lymphatic development and function,
including gain or loss of Vegf-c or Vegfr3 (28, 29), loss or muta-
tion of Ephrinb2 (30) or Ephb4 (31) and Rasa1 (10, 32), or gain of
function of Ras andErk (22, 33, 34). Furthermore, the similarity of
the phenotypes of these animalmodels andmice lacking endothe-
lial Map4k4 strongly suggested that Map4k4 functions within this
signaling pathway. Indeed, Map4k4 was previously identified as
an effector in the ephrin pathway in vitro, which forms a complex
with Rasa1 (19). Consistent with the known actions of Rasa1 to
inactivate Ras and Erk, enhanced Ras and Erk activities were ob-
served basally when Map4k4 was knocked down in vascular and
lymphatic ECs (Fig. 5). Furthermore, primary MLECs lacking
Map4k4 proliferated more (Fig. 4), concomitant with a reduced
population of cells in G2/M transition and alterations in cell cycle
gene expression (Fig. 4). Interestingly, a number of the genes af-
fected by Map4k4 loss are known Ras target genes (35), and Ras/
Erk activation is known to enhance proliferation rather than to
induce growth arrest in endothelial cells (36, 37), suggesting that
Map4k4mediates its effects on proliferation bymodulating G2/M
transition downstream of Ras. MLECs lacking Map4k4 also dis-
played a more “lymphatic” EC signature than Flox/Flox MLECs
(Fig. 5), suggesting that Map4k4 is important for EC quiescence
and lymphatic cell fate decisions.
In conclusion, the data presented here demonstrate that endo-
thelial Map4k4 is a critical regulator of lymphatic vascular devel-
opment. Map4k4 inhibitors are currently being developed for a
number of clinical uses (16, 38, 39). Importantly, the studies re-
ported here call the clinical safety ofMap4k4 inhibitors into ques-
tion due to potential lymphatic vascular sequelae, chyle leakage
phenotypes, and a potential to promote lymphangiogenesis and
tumor metastasis.
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